Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: The never-ending story

Journal of Clinical Oncology

Volumn 31, Issue 26, 2013, Pages 3291-3293

  Gelsomino, Francesco ^a   Agustoni, Francesco ^a   Niger, Monica ^a   Valota, Marika ^a   Haspinger, Eva R ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CYTOTOXICITY; DRUG APPROVAL; DRUG COST; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; NON SMALL CELL LUNG CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84891539497     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.2617     Document Type: Letter

References (29)

1. Laurie SA, Goss GD: Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer. J Clin Oncol 31:1061-1069, 2013
2. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
3. Han JY, Park K, Kim SW, et al: First-SIGNAL: First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30:1122-1128, 2012
4. Jänne PA, Wang X, Socinski MA, et al: Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol 30:2063-2069, 2012
5. Gatzemeier U, Pluzanska A, Szczesna A, et al: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545-1552, 2007
6. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899, 2005
7. Gridelli C, Ciardiello F, Gallo C, et al: First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial. J Clin Oncol 30:3002-3011, 2012
8. Lee SM, Khan I, Upadhyay S, et al: First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): A double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 13:1161-1170, 2012
9. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicenter, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529, 2010
10. Miller VA, O'Conner P, Soh C, et al: A randomized, double-blind, placebocontrolled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 27:407s, 2009 (suppl: abstr LBA8002)
11. Pérol M, Chouaid C, Pérol D, et al: Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 30:3516-3524, 2012
12. Gaafar RM, Surmont VF, Scagliotti GV, et al: A double-blind, randomised, placebo-controlled, phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer 47:2331-2340, 2011
13. Zhang L, Ma S, Song X, et al: Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): A multicentre, double-blind, randomised phase 3 trial. Lancet Oncol 13:466-475, 2012
14. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
15. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005
16. Kim ES, Hirsh V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomized phase III trial. Lancet 372:1809-1818, 2008
17. Maruyama R, Nishiwaki Y, Tamura T, et al: Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-smallcell lung cancer. J Clin Oncol 26:4244-4252, 2008
18. Lee DH, Park K, Kim JH, et al: Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 16:1307-1314, 2010
19. Vamvakas L, Agelaki S, Kentepozidis NK, et al: Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. J Clin Oncol 28:543s, 2010 (suppl; abstr 7519)
20. Ciuleanu T, Stelmakh L, Cicenas S, et al: Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study. Lancet Oncol 13:300-308, 2012
21. Douillard JY, Shepherd FA, Hirsh V, et al: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST Trial. J Clin Oncol 28:744-752, 2010
22. Garassino MC, Martelli O, Bettini A, et al: TAILOR: Phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. J Clin Oncol 30:480s, 2012 (suppl; abstr LBA7501)
23. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010
24. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomized phase 3 trial. Lancet Oncol 11:121-128, 2010
25. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicenter, open-label, randomized, phase 3 study. Lancet Oncol 12:735-742, 2011
26. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, openlabel, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
27. Yang JC-H, Schuler MH, Yamamoto N et al: LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 30:780s, 2012 (suppl; abstr LBA7500)
28. Nabhan C, Bitran JD: Erlotinib in lung cancer. N Engl J Med 353:1739-1741, 2005
29. Garassino MC, Marsoni S, Floriani I: Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: The other side of the coin. J Clin Oncol 29:3835-3837, 2011